Failure-to-warn claims against generic makers of Reglan are not preempted to the extent those companies failed to update the warnings on their labels, a New Jersey appeals court held Nov. 12.

The decision in In re Reglan Litigation potentially affects a large portion of the 650 or so pending lawsuits consolidated in Middlesex County, where they were transferred from Atlantic County at the end of October.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]